In this exploratory study, we investigated whether serum peptides as well as serum concentrations of haptoglobin, thrombocytes, YKL-40 and Fetuin-a, could predict treatment response in newly diagnosed GBM patients. The gene discussed is HP; the disease is glioblastoma.